X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs BIOCON LTD - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE BIOCON LTD CADILA HEALTHCARE/
BIOCON LTD
 
P/E (TTM) x 34.8 36.5 95.3% View Chart
P/BV x 9.0 4.9 184.6% View Chart
Dividend Yield % 0.7 1.5 44.8%  

Financials

 CADILA HEALTHCARE   BIOCON LTD
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-16
BIOCON LTD
Mar-16
CADILA HEALTHCARE/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs454496 91.7%   
Low Rs305397 76.8%   
Sales per share (Unadj.) Rs96.1174.3 55.1%  
Earnings per share (Unadj.) Rs14.944.8 33.2%  
Cash flow per share (Unadj.) Rs17.856.9 31.3%  
Dividends per share (Unadj.) Rs3.205.00 64.0%  
Dividend yield (eoy) %0.81.1 75.2%  
Book value per share (Unadj.) Rs52.3202.8 25.8%  
Shares outstanding (eoy) m1,023.74200.00 511.9%   
Bonus/Rights/Conversions FV5:1--  
Price / Sales ratio x3.92.6 154.3%   
Avg P/E ratio x25.510.0 256.2%  
P/CF ratio (eoy) x21.37.8 271.6%  
Price / Book Value ratio x7.32.2 329.9%  
Dividend payout %21.511.2 192.8%   
Avg Mkt Cap Rs m388,45889,220 435.4%   
No. of employees `00015.44.4 349.7%   
Total wages/salary Rs m13,3176,363 209.3%   
Avg. sales/employee Rs Th6,371.17,894.5 80.7%   
Avg. wages/employee Rs Th862.41,441.2 59.8%   
Avg. net profit/employee Rs Th986.12,029.7 48.6%   
INCOME DATA
Net Sales Rs m98,37634,854 282.3%  
Other income Rs m941845 111.4%   
Total revenues Rs m99,31735,699 278.2%   
Gross profit Rs m23,8298,200 290.6%  
Depreciation Rs m3,0222,423 124.7%   
Interest Rs m486102 476.5%   
Profit before tax Rs m21,2626,520 326.1%   
Minority Interest Rs m-300-744 40.3%   
Prior Period Items Rs m50-   
Extraordinary Inc (Exp) Rs m-255,754 -0.4%   
Tax Rs m5,7162,569 222.5%   
Profit after tax Rs m15,2268,961 169.9%  
Gross profit margin %24.223.5 103.0%  
Effective tax rate %26.939.4 68.2%   
Net profit margin %15.525.7 60.2%  
BALANCE SHEET DATA
Current assets Rs m44,37639,932 111.1%   
Current liabilities Rs m34,07116,276 209.3%   
Net working cap to sales %10.567.9 15.4%  
Current ratio x1.32.5 53.1%  
Inventory Days Days5454 100.5%  
Debtors Days Days6286 72.3%  
Net fixed assets Rs m47,89639,101 122.5%   
Share capital Rs m1,0241,000 102.4%   
"Free" reserves Rs m48,74638,591 126.3%   
Net worth Rs m53,51940,556 132.0%   
Long term debt Rs m8,96420,724 43.3%   
Total assets Rs m100,16384,816 118.1%  
Interest coverage x44.764.9 68.9%   
Debt to equity ratio x0.20.5 32.8%  
Sales to assets ratio x1.00.4 239.0%   
Return on assets %15.710.7 146.8%  
Return on equity %28.422.1 128.8%  
Return on capital %34.319.0 180.7%  
Exports to sales %45.330.7 147.2%   
Imports to sales %5.920.4 29.1%   
Exports (fob) Rs m44,53710,717 415.6%   
Imports (cif) Rs m5,8387,105 82.2%   
Fx inflow Rs m44,88111,789 380.7%   
Fx outflow Rs m9,0698,393 108.1%   
Net fx Rs m35,8123,396 1,054.5%   
CASH FLOW
From Operations Rs m19,9385,264 378.8%  
From Investments Rs m-9,039-9,540 94.7%  
From Financial Activity Rs m-9,52710,867 -87.7%  
Net Cashflow Rs m1,3726,591 20.8%  

Share Holding

Indian Promoters % 74.8 40.4 185.1%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 8.3 8.4 98.8%  
FIIs % 5.9 10.7 55.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 19.9 55.3%  
Shareholders   44,069 109,995 40.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   SUN PHARMA  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  MERCK LTD  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

Sep 19, 2016

Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Aug 22, 2017 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS